Kymera Therapeutics KYMR
NASDAQ KYMR
$117.45 +0.17 (+0.14%)
As of: Sep 4, 2026 · 3:59 PM EDT

Kymera Therapeutics (KYMR) Revenue Growth (3y) (2022 - 2026)

Analysis

Kymera Therapeutics (KYMR) Revenue Growth (3y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 10.17%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 10.76%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 77.85%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -25.02%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 42.02%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 59.40%
8 Royalty Pharma 28.45 Bn 27.61 Bn - 7.80%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 76.62%
10 Kymera Therapeutics 11.52 Bn 10.83 Bn - 57.89%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 57.89%
Mar 31, 2026 53.69%
Dec 31, 2025 -43.77%
Sep 30, 2025 -33.86%
Jun 30, 2025 -0.11%
Mar 31, 2025 31.94%
Dec 31, 2024 -21.48%
Sep 30, 2024 -43.13%
Jun 30, 2024 11.47%
Mar 31, 2024 -18.07%
Dec 31, 2023 55.30%
Sep 30, 2023 -31.22%
Jun 30, 2023 71.25%
Mar 31, 2023 40.29%
Dec 31, 2022 106.49%
Sep 30, 2022 115.83%